| Basics |
Adverum Biotechnologies, Inc.
Adverum Biotechnologies Inc is a gene therapy company committed to discovering and developing novel medicines that can offer potentially life-changing therapeutic benefit to patients living with rare diseases or diseases of the eye.
|
| IPO Date: |
May 12, 2016 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$94.05M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.20 | 3.64%
|
| Avg Daily Range (30 D): |
$0.06 | 1.41%
|
| Avg Daily Range (90 D): |
$0.14 | 3.65%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.72M |
| Avg Daily Volume (30 D): |
.81M |
| Avg Daily Volume (90 D): |
.46M |
| Trade Size |
| Avg Trade Size (Sh.): |
171 |
| Avg Trade Size (Sh.) (30 D): |
153 |
| Avg Trade Size (Sh.) (90 D): |
139 |
| Institutional Trades |
| Total Inst.Trades: |
1,059 |
| Avg Inst. Trade: |
$1.82M |
| Avg Inst. Trade (30 D): |
$.88M |
| Avg Inst. Trade (90 D): |
$.88M |
| Avg Inst. Trade Volume: |
.04M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.18M |
| Avg Closing Trade (30 D): |
$4.03M |
| Avg Closing Trade (90 D): |
$4.03M |
| Avg Closing Volume: |
33.19K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$-8.57
|
$-2.03
|
$-2.34
|
|
Diluted EPS
|
$-8.57
|
$-2.03
|
$-2.34
|
|
Revenue
|
$ M
|
$ M
|
$ M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -184.79M
|
$ -47.65M
|
$ -49.19M
|
|
Operating Income / Loss
|
$ -188.72M
|
$ -48.02M
|
$ -49.86M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ -66.79M
|
$ -16.36M
|
$ -18.23M
|
|
PE Ratio
|
|
|
|
| Splits |
|
Mar 21, 2024:
1:10
|
|
|
|
